Hassan Alhosaini, MD
Advanced Heart Failure and Transplant Cardiology · Winston Salem, NCNPI 1144200734
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $175,828 of the $194,970 with a category attached, or 90.2%. Actelion Pharmaceuticals US, Inc. accounts for 82.8% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $52,818 and has fallen 68.9% since, to $16,428 in 2025.
Across 251 payments — averaging $776.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$161K
- Novartis$27K
- Abbott$6K
- Pfizer$121
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$68
- Abiomed$65
- plus $417 from 12 others
Across 77 payments — averaging $2582.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$82K
- Novartis$76K
- Vifor (international) Ltd.$29K
- Janssen Research & Development, LLC$12K
What the payments were for
- Consulting fees$5,1503%
- Speaking & faculty fees$175,82890%
- Travel & lodging$7,8114%
- Food & beverage$6,1613%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 142 | $161,458 |
| Novartis | 24 | $27,226 |
| Abbott | 50 | $5,615 |
| Pfizer | 5 | $121 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $68 |
| Abiomed | 2 | $65 |
| Merck | 2 | $64 |
| Baxter Healthcare | 3 | $56 |
| E.r. Squibb & Sons, L.L.C. | 3 | $47 |
| United Therapeutics Corporation | 3 | $45 |
| Novo Nordisk | 2 | $40 |
| Sanofi-aventis U.S. LLC | 2 | $39 |
| Vital Connect, Inc | 1 | $33 |
| Amgen | 2 | $32 |
| Johnson & Johnson | 3 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| AstraZeneca | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPSUMIT$146,150
- UPTRAVI$132,629
- ENTRESTO$26,525
- CardioMEMS HF System$2,000
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$1,863
- HeartMate 3 Left Ventricular Dev$263
- CARDIOMEMS$174
- Mitra Clip system$149
How this compares
$194,970 in reported general payments places this provider in the 85th percentile of 31 advanced heart failure and transplant cardiology providers in North Carolina.
See all advanced heart failure and transplant cardiology providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 33 | $815,846 |
| Tyvaso DpiTreprostinil | 22 | $546,877 |
| VyndamaxTafamidis | 25 | $541,767 |
| CamzyosMavacamten | 38 | $321,309 |
| OpsumitMacitentan | 22 | $275,130 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $161,458 | $1,090,97655 claims |
| PfizerVyndamax | $121 | $541,76725 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $47 | $321,30938 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 31 advanced heart failure and transplant cardiology providers in North Carolina.
Other advanced heart failure and transplant cardiology in Winston Salem
- Barbara PisaniWinston Salem$3K
- Aysha AmjadWinston Salem$381
- Daniel BensimhonGreensboro$2.1M
- Stephen GreeneDurham$582K
- John RommelWilmington$263K
- Stephen ZouzoulasConcord$244K
- Vinay ThohanAsheville$164K
- Kishan ParikhRaleigh$158K
- Emil MissovGreenville$71K
- David IshizawarRaleigh$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.